Bayers assessment.

Bayers assessment.

Posted at 2:37 am on June 28th, 2017

Bayer affirms the positive benefit-risk profile of its drospirenone – containing oral contraceptives Bayer HealthCare Pharmaceuticals knows two research published in The Uk Medical Journal . These papers are ‘Threat of venous thromboembolism in users of oral contraceptives made up of drospirenone or levonorgestrel: nested case-control study predicated on UK General Practice Analysis Data source’ by Lianne Parkin et al ; and ‘Threat of nonfatal venous thromboembolism in ladies using oral contraceptives containing drospirenone weighed against ladies using oral contraceptives containing levonorgestrel: case-control research using United States statements data’ by Susan S.


Bayer submits first-in-course estradiol-based oral contraceptive for acceptance in the US Bayer offers submitted a fresh Drug Software to the U.S. Food and Medication Administration for a fresh estradiol-centered oral contraceptive . It seeks authorization for the indications oral medication and contraception of heavy and/or prolonged menstrual bleeding. The new item with an estradiol valerate/dienogest combination may be the first in a fresh course of oral contraceptives to provide estradiol, the estrogen similar to the one made by the feminine body. We are very happy to be able to post the NDA because of this fresh estradiol-structured oral contraceptive in the U.S. Just a few weeks after Qlaira’s start in European countries, stated Phil Smits, M.D. We visit a high curiosity in this fresh oral contraceptive by ladies and gynecologists.

Random Articles

Other Articles From Category "care":